blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3967326

EP3967326 - IMMUNOGENIC COMPOSITIONS [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  30.09.2022
Database last updated on 14.09.2024
FormerThe application has been published
Status updated on  11.02.2022
Most recent event   Tooltip30.09.2022Refusal of applicationpublished on 02.11.2022  [2022/44]
Applicant(s)For all designated states
Immunethep, SA
Biocant Park, Núcleo 4 Lote 3
3060-197 Cantanhede / PT
[2022/11]
Representative(s)Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
[2022/11]
Application number, filing date20398008.110.09.2020
[2022/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3967326
Date:16.03.2022
Language:EN
[2022/11]
Search report(s)(Supplementary) European search report - dispatched on:EP15.04.2021
ClassificationIPC:A61K39/12, A61P31/14
[2022/11]
CPC:
A61K39/12 (EP); A61P31/14 (EP); A61K2039/5252 (EP);
A61K2039/5254 (EP); A61K2039/543 (EP); A61K2039/544 (EP);
A61K2039/55561 (EP); C12N2770/20034 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:IMMUNOGENE ZUSAMMENSETZUNGEN[2022/11]
English:IMMUNOGENIC COMPOSITIONS[2022/11]
French:COMPOSITIONS IMMUNOGÈNES[2022/11]
Examination procedure13.06.2022Despatch of communication that the application is refused, reason: Examination on filing A.90(5) [2022/44]
23.06.2022Application refused, date of legal effect [2022/44]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]  - GAO QIANG ET AL, "Development of an inactivated vaccine candidate for SARS-CoV-2", SCIENCE, US, vol. 369, no. 6499, doi:10.1126/science.abc1932, ISSN 0036-8075, (20200703), pages 77 - 81, URL: https://science.sciencemag.org/content/sci/369/6499/77.full.pdf, (20210315), XP055785035 [X] 1,5-7,9,12 * the whole document * [Y] 2,3,8,10,11,14,15

DOI:   http://dx.doi.org/10.1126/science.abc1932
 [Y]  - Anonymous, "Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19) - Full Text View - ClinicalTrials.gov", (20200420), URL: https://clinicaltrials.gov/ct2/show/study/NCT04352608, (20210312), XP055785333 [Y] 2,3,8,10,11,14,15 * the whole document *
 [Y]  - WANG HUI ET AL, "Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2", CELL, ELSEVIER, AMSTERDAM NL, vol. 182, no. 3, doi:10.1016/J.CELL.2020.06.008, ISSN 0092-8674, (20200606), page 713, (20200606), XP086239951 [Y] 2,3,8,10,11,14,15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cell.2020.06.008
 [Y]  - Anonymous, "Codagenix Announces the Synthesis and Preliminary Safety of Scalable, Live-attenuated Vaccine Candidate Against COVID-19 - SynBioBeta", (20200618), URL: https://synbiobeta.com/codagenix-announces-the-synthesis-and-preliminary-safety-of-scalable-live-attenuated-vaccine-candidate-against-covid-19/, (20210315), XP055785558 [Y] 2,3,8,10,11,14,15 * the whole document *
 [XP]  - Codagenix ET AL, "Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate", (20200922), URL: https://www.prnewswire.com/news-releases/serum-institute-of-india-initiates-manufacturing-of-codagenixs-intranasal-live-attenuated-covid-19-vaccine-candidate-301135221.html, (20210315), XP055785595 [XP] 1-4,12-15 * the whole document *
 [Y]  - GAI WEI-WEI ET AL, "PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV", VIROLOGICA SINICA, SPRINGER, DE, vol. 26, no. 2, doi:10.1007/S12250-011-3183-Z, ISSN 1674-0769, (20110401), pages 81 - 94, (20110407), XP037068928 [Y] 2,3,8,10,11,14,15 * the whole document *

DOI:   http://dx.doi.org/10.1007/s12250-011-3183-z
by applicant   - WANG, C. et al., J Med Virol, (20200000), vol. 92, pages 667 - 674
    - ZHOU, P. et al., Nature, (20200000), vol. 579, no. 7798, pages 270 - 273
    - "NCBI", Database accession no. NC 045512.2
    - YUSUF, H. et al., Hum Vacc Immunother, (20170000), vol. 13, no. 1, pages 34 - 45
    - OKADA, H. et al., J Clin Oncol, (20110000), vol. 29, no. 3, pages 330 - 336
    - NG, M.L. et al., J Gen Virol, (20030000), vol. 84, no. 12, pages 3291 - 3303
    - KEYAERTS, E. et al., Biochem Biophys Res Commun, (20050000), vol. 329, no. 3, pages 1147 - 1151
    - BERNSTEIN, D.I., Semin Pediatr Infect Dis, (20060000), vol. 17, no. 4, pages 188 - 194
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.